Adaptive designs from the viewpoint of an academic biostatistician.
This is a discussion of the following three papers appearing in this special issue on adaptive designs: 'FDA's critical path initiative: A perspective on contributions of biostatistics' by Robert T. O'Neill, 'A regulatory view on adaptive/flexible clinical trial design' by H. M. James Hung, Robert T. O'Neill, Sue-Jane Wang and John Lawrence; and 'Confirmatory clinical trials with an adaptive design' by Armin Koch.
Schäfer
Helmut
H
Institute of Medical Biometry and Epidemiology, Philipps-University Marburg, Germany. hsimbe@med.uni-marburg.de
D001699:Biometry; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D003627:Data Interpretation, Statistical; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012107:Research Design / Q000706:statistics & numerical data*; D018401:Sample Size